


Idis Pharma Limited

Directors' Report and Unaudited Financial Statements

For the period ended 31 January 2017

Company Number: 09964075

WEDNESDAY



A6HAV9Q2

A22

18/10/2017

#336

COMPANIES HOUSE

Idis Pharma Limited

Directors' Report for the period ended 31 January 2017

The directors present their report together with the financial statements of Idis Pharma Limited (the "Company") for the period ended 31 January 2017. This is the first period of account following the Company's incorporation on 21 January 2016. The Company's registered number is 09964075.

Principal activity

The Company is dormant and has not traded during the period, therefore no profit and loss account is presented. The directors have prepared this report in accordance with the special provisions relating to small companies within Part 16 of the Companies Act 2006. The Company was entitled to exemption from audit under Section 480 of the Companies Act 2006. The directors have taken advantage of the small companies' exemption in Section 172 of the Companies Act 2006 and not prepared a strategic report for the period.

Directors and company secretary

The directors holding office during the period and up to the date of signing this report were:

S Chilton
M Abell
P George (resigned 11 November 2016)

The company secretary at the date of signing this report is A Miller.
The registered office is Pitcairn House, Crown Square, First Avenue, Burton-On-Trent, Staffordshire, DE14 2WW.

Insurance and third party indemnification

During the period and up to the date of signing this report, the Company, through its parent group, maintained liability insurance and third party indemnification provisions for its directors and the company secretary.

Statement of directors' responsibilities


The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial period. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the Board



M Abell
Director
16 October 2017

Idis Pharma Limited

Balance sheet at 31 January 2017

Company number 09964075	Note	2017 £
Current assets		
Debtors	3	1
Net assets		1
Capital and reserves		
Called up share capital	4	1
Shareholders' funds		1

The Company did not trade during the period under review and so no profit and loss account or statement of changes in total equity have been prepared. The Company has not received any income, incurred any expense or recognised any other gains or losses.

For the period ended 31 January 2017, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies. The members have not required the Company to obtain an audit of its financial statements for the period ended 31 January 2017 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 2 and 3 were approved by the board and authorised for issue on 16 October 2017.



M Abell
Director

Idis Pharma Limited

Notes to the financial statements for the period ended 31 January 2017

1 Accounting policies

Basis of preparation of financial statements

These financial statements have been prepared under the historical cost convention in compliance with United Kingdom accounting standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102"), and the Companies Act 2006. The Company has adopted FRS 102 in these financial statements. There were no changes impacting the financial statements on adopting FRS 102.

Reporting currency

These financial statements are presented in sterling, the Company's functional currency

2 Profit and loss account and statement of comprehensive income

The Company did not trade during the period and accordingly no profit and loss account is presented. It had no other income or charges and accordingly no statement of comprehensive income is presented.

The Company had no employees during the period and accordingly no employee costs are included in these financial statements. No directors received any remuneration in respect of their services to the Company.

3 Debtors

	2017 £
Amounts owed by group undertakings	1

The amounts owed by group undertakings are non-interest bearing and receivable on demand.

4 Share capital

	2017 £
Issued, allotted, called up and fully paid 1 ordinary share of £1 each	1

5 Ultimate parent undertaking and controlling party

The Company is a wholly owned subsidiary undertaking of Idis Limited. The Company's ultimate parent undertaking and controlling party is Clinigen Group plc, a company registered in the United Kingdom.

Clinigen Group plc is the parent undertaking of the smallest and largest group of which the Company is a member. The consolidated financial statements of this group may be obtained from Pitcairn House, Crown Square, Centrum 100, Burton-on-Trent, Staffordshire, DE14 2WW.